Cynthia A. Schandl, MD, PhD, discusses the role of the pathologist in expediting biomarker-driven treatment decisions in lung cancer care.
Cynthia A. Schandl, MD, PhD
Advertisement
Cynthia A. Schandl, MD, PhD is the Medical Director of Clinical Laboratories/Director of the Division of Clinical Pathology.
Articles by Cynthia A. Schandl, MD, PhD
Adam Fox, MD, and Cynthia A. Schandl, MD, PhD, examined the expanding role of biomarker testing and genomic profiling in NSCLC across disease stages.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers
5